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An elevated low-density lipoprotein cholesterol (LDL-C) is
a causal risk factor for the development of coronary artery
disease (CAD). In both its native and oxidized forms,
LDL-C causes direct endothelial cell injury and dysfunc-
tion, predisposing to an inflammatory response in the artery
wall that promotes the development of an atherosclerotic
plaque (1,2). Whether through subsequent plaque rupture
(or plaque erosion) with superimposed thrombosis or
through flow limitation from high-grade stenosis, the ath-
erosclerotic plaque plays a key role in the myriad manifes-
tations of ischemic heart disease.
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Over the past 30 years, the link between dyslipidemia and
atherosclerosis has been firmly established (3). Both primary
and secondary prevention trials have shown that a reduction
in cholesterol levels translates into a reduction in cardiovas-
cular disease (CVD) event rates (4,5). Despite this, angio-
graphic studies have demonstrated only minimal decre-
ments in coronary artery stenosis with cholesterol reduction
(6,7). Furthermore, there does not appear to be a strong
correlation between the severity of a given stenosis and the
likelihood of a future acute ischemic event at that particular
site (8). As such, cholesterol-lowering therapies are believed
to derive much of their benefit through direct changes in the
endothelium, independent of atherosclerotic regression.
Of the numerous available cholesterol-lowering therapies,
the 3-hydroxy-3-methylglutaryl-coenzyme A reductase in-
hibitors (statins) are most commonly used. Based on serial
quantitative coronary angiography, several studies have
demonstrated an improvement in endothelial function fol-
lowing statin therapy (9,10). This has also been noted in
studies using stress myocardial perfusion imaging (MPI)
and is likely based on the ability of MPI to detect athero-
sclerotic lesions associated with dysfunctional endothelium
(11–13). Because stress MPI is noninvasive and associated
with significant prognostic value, it serves as an important
tool to better understand how statins affect the atheroscle-
rotic process (14).
Contributions of the current article. In this issue of the
Journal, Schwartz et al. (15) make several observations that
improve our understanding of how statins affect coronary
atherosclerosis. In this study, patients treated with prava-
statin were prospectively evaluated with stress and rest MPI
to better delineate the temporal magnitude of changes in
myocardial perfusion associated with statin therapy and to
correlate this with the amount of cholesterol reduction.
Twenty-five patients with a baseline LDL-C of 134  31
mg/dl were treated with 40 mg of daily pravastatin. At six
weeks and at six months, there were 32% and 28% reduc-
tions in the mean LDL-C respectively (p  0.001). This
degree of LDL-C reduction was similar to that observed in
other larger clinical trials of pravastatin, such as the Cho-
lesterol And Recurrent Events (CARE) trial (4). Significant
improvement in stress-induced MPI was noted in one-half
of the patients at six months, but there was no significant
change at six weeks. This is consistent with previous reports
of improvement in stress myocardial perfusion within four
months using positron emission tomography MPI (11,16)
and at 3 to 12 months using single photon emission
computed tomography MPI (12,17,18).
One of the more interesting findings of this study was the
poor correlation noted between an improvement in MPI
and the lipid profile at six months. Among the 21 patients
with a significant reduction in LDL-C, only 9 (43%) had a
significant improvement in MPI, although several subjects
normalized their perfusion scans. In contrast, of the two
patients without a significant improvement in LDL-C, both
had clear improvement in MPI. This suggests that there is
heterogeneity in the way that patients respond to statins
despite similar improvements in their lipid profile. Statins
are thought to have pleiotropic effects that may not be
reflected in the change in calculated LDL-C values; some of
these proposed effects include anti-inflammatory, anti-
thrombotic, immunologic, and plaque-stabilizing effects, as
well as an improvement in endothelial function (19).
It is unclear whether all of the patients included in this
study had at least mild atherosclerotic coronary disease or
not. Although each patient had abnormal MPI,40% were
referred for testing either because of chest pain or dyspnea
or because an evaluation was done for an abnormal electro-
cardiogram or the need for further preoperative risk strati-
fication. Assuming that each patient enrolled in this study
had “clinical CAD,” it is noteworthy that only 15 of 23
(65%) were on aspirin and 7 of 23 (30%) were on
angiotensin-converting enzyme inhibitors initially. During
the trial there was an increase in adherence to the ABCs of
secondary CVD prevention (aspirin, angiotensin-converting
enzyme inhibitors, beta-blockers, and cholesterol-lowering
therapy such as niacin) (20–22). Through their effects on
thrombosis, chronotropy, plaque inflammation, and coro-
nary stenosis, each of these “proven” medications may have
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affected endothelial function and vascular tone and, thus,
may have confounded follow-up perfusion findings.
Areas for future investigation. The exact mechanism and
timing by which statins exert their benefits on the athero-
sclerotic process are still not fully elucidated (18,23). A
variety of studies have documented improvements in myo-
cardial perfusion, endothelial function, and clinical events
with statins. The work presented by Schwartz et al. (15)
suggests that LDL-C reduction may not be the best way to
assess the clinical and vascular effects of statins. To fully
assess this, future studies using MPI as an end point for
high versus moderate dose statins or statins versus other
classes of cholesterol-lowering agents should be pursued.
In the CARE trial (4) the mean LDL-C was 139 mg/dl
and there was no separation of the event curves between the
statin and placebo treated groups until after two years of
treatment. In contrast, prior pravastatin trials with a much
higher baseline LDL-C demonstrated separation of the
curves within six months (5). Improvement in endothelial
function following statin therapy has been detected after as
little as four weeks of treatment (24). Myocardial perfusion
imaging appears to be a reliable means of detecting this
endothelial dysfunction (25), and improvements in MPI
have been associated with improved prognosis. Thus, it
appears to take considerable time for reduced LDL-C to be
reflected in fewer clinical events through pleiotropic effects
of the statins (such as improvement in endothelial function,
reduction in inflammation, plaque stabilization, or reduc-
tion in coronary atherosclerosis), especially if the baseline
LDL-C is not markedly elevated.
For more than 15 years, our group has used MPI to look
for occult CAD in asymptomatic siblings of persons with
premature CAD, a group with a high prevalence of multiple
coronary risk factors (Johns Hopkins Sibling Study) (26).
We have shown that mild to moderate coronary atheroscle-
rosis is usually present at angiography in people with
abnormal MPI and that the noted perfusion defects may
represent areas of abnormal coronary vasomotor function in
a segment of dysfunctional endothelium or diffuse mild
small vessel disease (13). In an apparently healthy popula-
tion at increased risk because of a positive family history, we
have demonstrated that MPI is a useful means of risk
assessment for subsequent coronary heart disease events;
high-risk siblings with abnormal perfusion scans had a
relative risk of almost five times that of siblings with normal
MPI at a mean of 6.2 years of follow-up (27). These
findings underscore the benefits of baseline MPI and
strongly argue for its use in future investigation to refine the
evaluation of risk and perhaps to even identify the impact of
statin therapy in very high-risk populations.
Nonetheless, gaps still exist in our understanding of how
statins affect the atherosclerotic process. It is likely that
there are genetic determinants of statin responsiveness,
whereby the presence or absence of different risk factors may
affect the ways in which patients respond to statins. As such,
we need to better understand: 1) why patients with similar
LDL-C reductions following statin therapy have variable
degrees of improved myocardial perfusion; 2) whether the
absolute LDL-C level is a reliable surrogate marker for
statin responsiveness or whether other indices such as the
percent change or absolute decrease in mg/dl of LDL-C
better predict this process; and 3) how MPI can be used to
identify potential statin responders and nonresponders from
a vascular perspective, not just from a lipid perspective.
The answers to these questions would enhance our
capacity to tailor therapy more appropriately, by augment-
ing (adding niacin or a fibrate) or changing a patient’s
lipid-lowering therapy as needed. Finally, this study leads us
to take a closer look at how MPI can be used to accurately
predict those individuals at increased risk of CVD events. In
an era where the utilization of statins continues to grow, a
better understanding of their short- and long-term mecha-
nisms of action is strongly needed.
Reprint requests and correspondence: Dr. Roger S. Blumen-
thal, Director, Ciccarone Preventive Cardiology Center, Carnegie
538, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore,
Maryland 21287. E-mail: rblument@jhmi.edu.
REFERENCES
1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med
1999;340:115–26.
2. Libby P. Current concepts of the pathogenesis of the acute coronary
syndromes. Circulation 2001;104:365–72.
3. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum
cholesterol, lipoproteins, and the risk of coronary heart disease. The
Framingham study. Ann Intern Med 1971;74:1–12.
4. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on
coronary events after myocardial infarction in patients with average
cholesterol levels. Cholesterol and Recurrent Events Trial investiga-
tors. N Engl J Med 1996;335:1001–9.
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart
disease with pravastatin in men with hypercholesterolemia. West of
Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:
1301–7.
6. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery
disease as a result of intensive lipid-lowering therapy in men with high
levels of apolipoprotein B. N Engl J Med 1990;323:1289–98.
7. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angio-
graphic changes with lovastatin therapy. The Monitored Atheroscle-
rosis Regression Study (MARS). The MARS Research Group. Ann
Intern Med 1993;119:969–76.
8. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in
patients with first myocardial infarction are not necessarily severe. Eur
Heart J 1988;9:1317–23.
9. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol
with pravastatin improves endothelium-dependent coronary vasomo-
tion in patients with hypercholesterolemia. Circulation 1994;89:2519–
24.
10. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of
cholesterol-lowering therapy on the coronary endothelium in patients
with coronary artery disease. N Engl J Med 1995;332:481–7.
11. Gould KL, Martucci JP, Goldberg DI, et al. Short-term cholesterol
lowering decreases size and severity of perfusion abnormalities by
positron emission tomography after dipyridamole in patients with
coronary artery disease. A potential noninvasive marker of healing
coronary endothelium. Circulation 1994;89:1530–8.
12. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger
G. Improvement of myocardial perfusion by short-term fluvastatin
therapy in coronary artery disease. Am J Cardiol 1995;76:122A–5A.
612 Blumenthal and Gluckman JACC Vol. 42, No. 4, 2003
Editorial Comment August 20, 2003:611–3
13. Blumenthal RS, Becker DM, Yanek LR, et al. Detecting occult
coronary disease in a high-risk asymptomatic population. Circulation
2003;107:702–7.
14. Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic
value of myocardial perfusion single photon emission computed
tomography for the prediction of cardiac death: differential stratifica-
tion for risk of cardiac death and myocardial infarction. Circulation
1998;97:535–43.
15. Schwartz RG, Pearson TA, Kalaria VG, et al. Prospective serial
evaluation of myocardial perfusion and lipids during the first six
months of pravastatin therapy: coronary artery disease regression single
photon emission computed tomography monitoring trial. J Am Coll
Cardiol 2003;42:600–10.
16. Huggins GS, Pasternak RC, Alpert NM, Fischman AJ, Gewirtz H.
Effects of short-term treatment of hyperlipidemia on coronary vaso-
dilator function and myocardial perfusion in regions having substantial
impairment of baseline dilator reverse. Circulation 1998;98:1291–6.
17. Mostaza JM, Gomez MV, Gallardo F, et al. Cholesterol reduction
improves myocardial perfusion abnormalities in patients with coronary
artery disease and average cholesterol levels. J Am Coll Cardiol
2000;35:76–82.
18. O’Rourke RA, Chaudhuri T, Shaw L, Berman DS. Resolution of
stress-induced myocardial ischemia during aggressive medical therapy
as demonstrated by single photon emission computed tomography
imaging. Circulation 2001;103:2315.
19. Sposito AC, Chapman MJ. Statin therapy in acute coronary syn-
dromes: mechanistic insight into clinical benefit. Arterioscler Thromb
Vasc Biol 2002;22:1524–34.
20. Braunstein JB, Cheng A, Fakhry C, Nass CM, Vigilance C, Blumen-
thal RS. ABCs of cardiovascular disease risk management. Cardiol Rev
2001;9:96–105.
21. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline
update for the management of patients with chronic stable angina—
summary article: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines
(Committee on the Management of Patients With Chronic Stable
Angina). Circulation 2003;107:149–58.
22. Blumenthal RS, Cohn G, Schulman SP. Medical therapy versus
coronary angioplasty in stable coronary artery disease: a critical review
of the literature. J Am Coll Cardiol 2000;36:668–73.
23. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am
Heart J 2000;139:577–83.
24. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme
A reductase inhibitor, improves endothelial function within 1 month.
Circulation 1997;95:1126–31.
25. Hasdai D, Gibbons RJ, Holmes DR, Jr., Higano ST, Lerman A.
Coronary endothelial dysfunction in humans is associated with myo-
cardial perfusion defects. Circulation 1997;96:3390–5.
26. Becker DM, Yook RM, Moy TF, Blumenthal RS, Becker LC.
Markedly high prevalence of coronary risk factors in apparently healthy
African-American and white siblings of persons with premature
coronary heart disease. Am J Cardiol 1998;82:1046–51.
27. Blumenthal RS, Becker DM, Moy TF, Coresh J, Wilder LB, Becker
LC. Exercise thallium tomography predicts future clinically manifest
coronary heart disease in a high-risk asymptomatic population. Cir-
culation 1996;93:915–23.
613JACC Vol. 42, No. 4, 2003 Blumenthal and Gluckman
August 20, 2003:611–3 Editorial Comment
